Novo Nordisk A/S (NVO) |
|
56.94 0.25 (0.44%)
|
12-10 16:02 |
|
Open: |
56.9 |
Pre. Close: |
56.69 |
|
High:
|
57.13 |
Low:
|
56.72 |
|
Volume:
|
851,701 |
Market Cap:
|
134553M |
|
|
|
|
Novo Nordisk A/S is a healthcare company. It is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The company's business segments include, diabetes and obesity care, and biopharmaceuticals. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
57.157 - 57.502 |
57.502 - 57.833 |
|
Low:
|
55.894 - 56.305 |
56.305 - 56.699 |
|
Close:
|
56.314 - 56.916 |
56.916 - 57.492 |
|
Technical analysis |
as of: 2019-12-10 4:33:00 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 67.76 One year: 79.14 |
| Support: |
Support1: 55.34 Support2: 53.69 |
| Resistance: |
Resistance1: 58.01 Resistance2: 67.76 |
| Pivot: |
56.16  |
| Moving Average: |
MA(5): 56.96  MA(20): 56.47
MA(100): 52.79 MA(250): 50.52 |
| MACD: |
MACD(12,26): 0.48 Signal(9): 0.52 |
| Stochastic oscillator: |
%K(14,3): 79.72 %D(3): 78.87 |
| RSI: |
RSI(14): 57.38 |
| 52-week: |
High: 58.01 Low: 43.60 Change(%): 23.8 |
| Average Vol(K): |
3-Month: 142286 10-Days: 129419 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.NVO has closed below upper band by 30.3%. Bollinger Bands are 5.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
2019-12-04
Biocon sees a sweet spot with its affordable insulin in US
BENGALURU: Biocon is planning to take its recombinant human (rh) insulin into the US market soon and has tabled an affordable price range for the diabetes drug to the US administration, the top executive of its subsidiary Biocon Biologics said.“If you look at rh-insulin, I think it’s very interesting currently to look at the United States…We are heavily focusing on policy work, how can we work with key stakeholders in an administration, or with the FDA (US Food and Drug Administration) and having a dialogue to show options,” Christiane Hamacher told ET.The Bengaluru-headquartered biotech firm is planning to provide rh-insulin to middle- and lowincome countries at less than 10 cents a day.It has also charted an affordable price point for the US, the third largest country with a diabetic population, which analysts have flagged as a crisis.Biocon Biologics is chasing a revenue target of $1 billion in financial year 2021-22. In the previous fiscal year, its revenue had topped $200 million.Biocon has launched two biosimilars in the US market – pegfilgrastim and trastuzumab for cancer treatment – with partner Mylan.Currently, rh-insulin prices are significantly higher and not covered under health insurance.
2019-11-28
Global Diabetes Care (Insulin, OAD & GLP-1) Market 2019-2023 - Key Players are Novo Nordisk, Sanofi, and Eli Lilly
DUBLIN, Nov. 28, 2019 /PRNewswire/ -- The "Global Diabetes Care Market (Insulin, OAD & GLP-1): Industry Analysis & Outlook (2019-2023)" report has been added to ResearchAndMarkets.com's offering. Diabetic population is growing considerably all over the world. AAMEO region is experiencing…
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Click here to get more fundamental analysis.
|
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: New York Stock Exchange |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
2350.00 |
| Shares Float (M) |
1680.00 |
|
% Held by Insiders
|
0.02 |
|
% Held by Institutions
|
9.41 |
|
Shares Short (K)
|
7190 |
|
Shares Short P. Month (K)
|
|
Stock Financials |
|
EPS
|
2.460 |
|
Book Value (p.s.)
|
3.080 |
|
PEG Ratio
|
2.48 |
|
Profit Margin
|
32.46 |
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
28.3 |
|
Return on Equity (ttm)
|
77.1 |
|
Qtrly Rev. Growth
|
9.1 |
|
Gross Profit (p.s.)
|
40.089 |
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
|
|
Qtrly Earnings Growth
|
12.80 |
|
Operating Cash Flow (M)
|
|
|
Levered Free Cash Flow (M)
|
|
Stock Valuations |
|
P/E
|
23.15 |
|
P/E Growth Ratio
|
|
|
P/BV
|
18.49 |
|
P/S
|
|
|
P/CF
|
|
Dividends & Splits |
|
Dividend
|
1.230 |
|
Dividend Yield
|
0.02 |
|
Dividend Pay Date
|
2019-08-27 |
|
Ex-Dividend Date
|
2019-03-22 |
|
Forward Dividend
|
1.250 |
|
Last Split Date
|
2014-01-09 |
|
Last Split Ratio
|
-1e+010 |
|
7 Binary Options
|
|
Your Ad Here
|
|
